Cargando…
p53-Dependent Cytoprotective Mechanisms behind Resistance to Chemo-Radiotherapeutic Agents Used in Cancer Treatment
SIMPLE SUMMARY: Acquired resistance to chemoradiotherapy is the common cause of relapse in cancer treatments. Although chemoradiotherapy often produces promising results early in treatment, most cancer patients develop resistance in the later stages and succumb to the disease. In this review, we att...
Autores principales: | Krishnaraj, Jayaraman, Yamamoto, Tatsuki, Ohki, Rieko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341282/ https://www.ncbi.nlm.nih.gov/pubmed/37444509 http://dx.doi.org/10.3390/cancers15133399 |
Ejemplares similares
-
P53 expression in hepatocellular carcinoma: influence on the radiotherapeutic response of the hepatocellular carcinoma
por: Lee, Yu Rim, et al.
Publicado: (2015) -
Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
por: Keeling, A. A., et al.
Publicado: (1989) -
p53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis
por: Chen, Yu, et al.
Publicado: (2020) -
Inhibition of post-transcriptional steps in ribosome biogenesis confers cytoprotection against chemotherapeutic agents in a p53-dependent manner
por: Sapio, Russell T., et al.
Publicado: (2017) -
Integrin Targeted Delivery of Radiotherapeutics
por: Liu, Zhaofei, et al.
Publicado: (2011)